secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0000950170-25-046110
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics reports 2024 net loss of $13.0M, cash $3.6M; raised $15M in private placement
--------------------------------------------------------------------------------

- Cash and investments $3.6M at Dec 31, 2024 vs $8.6M at Dec 31, 2023.
- Net loss $13.0M ($1.95 per share) in 2024 vs $13.3M ($4.24 per share) in 2023; operating loss $14.7M.
- Raised $15.0M via private placement, regains Nasdaq compliance and extends runway into 2026.
- FDA agreed on brand name REYOBIQ; orphan drug designation for leptomeningeal metastases in lung cancer.
- Appointed Dr. Michael Rosol as Chief Development Officer; Russell Bradley as President/GM of CNSide Diagnostics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000095017025046110/0000950170-25-046110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000095017025046110/pstv-20250327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-046110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer